These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 11816896)

  • 1. [Angiotensin II receptor antagonists reduce the development of nephropathies in type 2 diabetes. Three new studies are of interest, but don't answer all questions].
    Nilsson P; Attvall S
    Lakartidningen; 2001 Nov; 98(45):4960-2. PubMed ID: 11816896
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inhibition of the renin-angiotensin system in type 2 diabetes. New significant results concerning type 2 diabetes and renal disease].
    Mogensen CE
    Ugeskr Laeger; 2001 Oct; 163(40):5488. PubMed ID: 11601112
    [No Abstract]   [Full Text] [Related]  

  • 3. [Type 2 diabetes and nephropathy--new studies, new treatment strategies?].
    Os I; Stenehjem A; Høieggen A; Draganov B; Jenssen T; Holdaas H
    Tidsskr Nor Laegeforen; 2002 Apr; 122(9):918-20. PubMed ID: 12082835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Losartan and the kidney protection. The RENAAL study].
    Recenti Prog Med; 2001 Dec; 92(12):788. PubMed ID: 11822103
    [No Abstract]   [Full Text] [Related]  

  • 5. [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].
    Arner P
    Lakartidningen; 2002 Jan; 99(1-2):80-2. PubMed ID: 11871182
    [No Abstract]   [Full Text] [Related]  

  • 6. Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results.
    Remuzzi G; Ruggenenti P; Perna A; Dimitrov BD; de Zeeuw D; Hille DA; Shahinfar S; Carides GW; Brenner BM;
    J Am Soc Nephrol; 2004 Dec; 15(12):3117-25. PubMed ID: 15579515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Losartan in diabetic nephropathy.
    Perico N; Ruggenenti P; Remuzzi G
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the treatment of diabetic renal disease: focus on losartan.
    Rayner B
    Curr Med Res Opin; 2004 Mar; 20(3):333-40. PubMed ID: 15025842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Losartan ameliorates progression of glomerular structural changes in diabetic KKAy mice.
    Sasaki M; Uehara S; Ohta H; Taguchi K; Kemi M; Nishikibe M; Matsumoto H
    Life Sci; 2004 Jul; 75(7):869-80. PubMed ID: 15183078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin-Il-receptor blockers and nephropathy in patients with type 2 diabetes.
    Farquhar D
    CMAJ; 2001 Nov; 165(10):1379. PubMed ID: 11760990
    [No Abstract]   [Full Text] [Related]  

  • 11. [Angiotensin II antagonist also protects the kidneys. 2 dialysis-free years for diabetics].
    MMW Fortschr Med; 2001 Oct; 143(43):50. PubMed ID: 11715881
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of losartan on albuminuria, peripheral and autonomic neuropathy in normotensive microalbuminuric type 2 diabetics.
    Kubba S; Agarwal SK; Prakash A; Puri V; Babbar R; Anuradha S
    Neurol India; 2003 Sep; 51(3):355-8. PubMed ID: 14652437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.
    Carr AA; Kowey PR; Devereux RB; Brenner BM; Dahlöf B; Ibsen H; Lindholm LH; Lyle PA; Snapinn SM; Zhang Z; Edelman JM; Shahinfar S
    Am J Cardiol; 2005 Dec; 96(11):1530-6. PubMed ID: 16310435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing nephropathy in patients with type 2 diabetes.
    Manag Care Interface; 2002 Jan; 15(1):72-5. PubMed ID: 11828609
    [No Abstract]   [Full Text] [Related]  

  • 16. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.
    Eijkelkamp WB; Zhang Z; Remuzzi G; Parving HH; Cooper ME; Keane WF; Shahinfar S; Gleim GW; Weir MR; Brenner BM; de Zeeuw D
    J Am Soc Nephrol; 2007 May; 18(5):1540-6. PubMed ID: 17409317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The protective effect of blocking angiotensin in both type I and type II diabetics with nephropathy.
    Beevers DG; Lip GY
    J Hum Hypertens; 2001 Dec; 15(12):837-9. PubMed ID: 11773985
    [No Abstract]   [Full Text] [Related]  

  • 18. Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.
    Keane WF; Lyle PA;
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S22-5. PubMed ID: 12612946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The role of angiotensin II AT1-receptor antagonists in renal and cardiac protection in type-2 diabetes mellitus].
    Ravera M; Deferrari L; Ratto E; Vettoretti S; Parodi D; Deferrari G
    Ital Heart J Suppl; 2003 Mar; 4(3):210-6. PubMed ID: 12784755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.